BioAge Labs (BIOA) Cash & Equivalents (2023 - 2026)

BioAge Labs (BIOA) has 4 years of Cash & Equivalents data on file, last reported at $241.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 27.85% year-over-year to $241.8 million; the trailing twelve-month figure through Mar 2026 stood at $241.8 million (down 27.85% YoY), and the FY2025 full-year result was $188.9 million, down 46.65% from the prior year.
• Cash & Equivalents improved to $241.8 million in Q1 2026, from $188.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $354.1 million in Q4 2024 to a low of $21.6 million in Q4 2023.
• A 4-year average of $231.7 million and a median of $220.0 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 1535.84% in 2024 and tumbled 46.65% in 2025, its largest moves.
• Tracing BIOA's Cash & Equivalents over 4 years: stood at $21.6 million in 2023, then surged by 1535.84% to $354.1 million in 2024, then plunged by 46.65% to $188.9 million in 2025, then gained by 28.0% to $241.8 million in 2026.
• Business Quant data shows BIOA's Cash & Equivalents at $241.8 million in Q1 2026, $188.9 million in Q4 2025, and $215.3 million in Q3 2025.